DeCure for Immunodeficiency due to CD25 deficiency
DeCure's autonomous Immuno AI scientist is researching a drug-repurposing hypothesis for immunodeficiency due to CD25 deficiency — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleImmunodeficiency due to CD25 deficiency maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for immunodeficiency due to cd25 deficiency is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
CD44 molecule (IN blood group) (CD44) — CD44 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1UUH · 2.2 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Immunoglobulin therapy reduces the frequency and severity of infections in patients with significant antibody deficiencies, and its formulations and delivery methods have improved over time. No study in this set tests immunoglobulin in CD25 deficiency specifically; the evidence comes from general immunodeficiency populations.
In HIV infection, a disease that also involves immunodeficiency, the percentage of memory CD25+CD127loCD4+ T-regulatory cells increases as CD4+ T cells decline, while the percentage of naive CD25+CD127loCD4+ T-regulatory cells decreases. Lower numbers of total, memory, and naive CD25+CD127loCD4+ T cells correlate with higher immune activation, and a higher percentage of these T-reg cells is associated with lower Candida- and HIV-specific immune responses. The authors conclude that these CD25-expressing T-reg cells contribute to the immunodeficiency seen in HIV disease.
For severe combined immunodeficiency due to mutations in the CD45 gene, a separate primary immunodeficiency, therapeutic options include prophylactic anti-infective measures, haematopoietic stem cell transplantation, and gene therapy. No abstract in this set reports outcomes of any treatment for CD25 deficiency itself.
What is still missing is any clinical trial of immunoglobulin or any other therapy specifically in patients with confirmed CD25 deficiency, along with the funding and patient stratification needed to conduct such a study.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Immunotherapy · 2014 · 62 citations · open access
An Update on the Use of Immunoglobulin for the Treatment of Immunodeficiency Disorders
AbstractFor patients with significant antibody deficiencies, immunoglobulin therapy is the mainstay of treatment as it significantly reduces both the frequency and severity of infections. The formulations and delivery methods of immunoglobulin have evolved over time, and continued improvements have allowed for increased access to this effective medication. This review is an update on the current status of immunoglobulin therapy in immunodeficiency disorders, and discusses the mechanisms, forms and dosing, and indications for immunoglobulin replacement.
The Relationship of T-Regulatory Cell Subsets to Disease Stage, Immune Activation, and Pathogen-Specific Immunity in HIV Infection
AbstractBACKGROUND: Human immunodeficiency virus (HIV) infection is associated with abnormalities in T-regulatory (T-reg) cells, but the effect of HIV on the naive (CD45RO-) and memory (CD45RO) CD25+CD127loCD4+ T-reg cell subsets has not been defined. METHODS: We measured the absolute number and relative percentage of total, naive, and memory T-reg cells in HIV-infected subjects and compared these parameters with their CD4+ T cells, viral load, levels of immune activation, and pathogen-specific immunity. RESULTS: HIV infection was associated with an increased percentage of memory CD25+CD127loCD4+ T-reg cells and a decreased percentage of naive CD25+CD127loCD4+ T-reg cells as CD4+ T cells declined. The level of HIV viremia inversely correlated with total, memory, and naive CD25+CD127loCD4+ T-reg cell numbers and percentage of naive CD25+CD127loCD4+ T-reg cells. Lower total, memory, and naive CD25+CD127loCD4+ T-cell numbers were associated with higher levels of immune activation, whereas a higher percentage of CD25+CD127loCD4+ T-reg cells was associated with lower Candida- and HIV-specific immune responses. CONCLUSIONS: These observations suggest that CD25+CD127loCD4+ T-reg cells contribute to the immunodeficiency seen in HIV disease.
Oxford University Press eBooks · 2013 · 0 citations
Severe Combined Immunodeficiency Due to Mutations in the CD45 Gene
AbstractPrimary immunodeficiency diseases are inherited disorders that affect human adaptive and innate immunity. In most cases, affected individuals experience recurrent infections, but they may also suffer from autoimmune diseases and malignancies. This chapter focuses on Severe Combined Immunodeficiency Due to Mutations in the CD45 Gene, including the historic and scientific background, clinical presentations, immunologic characteristics, and the molecular/genetic underpinnings. Where appropriate, diagnostic tools and therapeutic options are outlined -- from prophylactic anti-infective measures to hematopoietic stem cell transplantation and gene therapy.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
